Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SCN1A | P35498 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424374 | 0.98 | CA1 (0.44) | CA2CA1CES2CES1MMP2 | |
| SCHEMBL4424378 | 0.86 | P2RX7 (0.55) | P2RX7MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL4420587 | 0.86 | CA1 (0.48) | CA2CA1CES2CES1MMP2 | |
| SCHEMBL6380635 | 0.85 | CA2 (0.46) | CA2CA1CES2CES1MMP2 | |
| SCHEMBL4431502 | 0.84 | MEN1 (0.49) | CA2CA1CES2CES1MMP2 | |
| SCHEMBL4553091 | 0.84 | TYMS (0.47) | CA2CA1CES2CES1CYP1A2 | |
| SCHEMBL4431500 | 0.84 | MEN1 (0.48) | CA2CA1CES2CES1MMP2 | |
| SCHEMBL4420586 | 0.84 | CA1 (0.48) | CA2CA1CES2CES1MMP2 | |
| SCHEMBL3213558 | 0.83 | ALDH1A1 (0.53) | CA2CA1CES2CES1MMP2 | |
| SCHEMBL6380631 | 0.83 | CA2 (0.46) | CA2CA1CES2CES1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | METHYLGENE, INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-7259172-B2 | phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance | METHYLGENE INC. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-20060105999-A1 | Novel inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2006-05-18 | — | — | US | disclosed |
| US-7030103-B2 | Sulfonamidomethyl phosphonate inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2006-04-18 | — | — | US | disclosed |
| EP-1194436-B1 | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2005-11-30 | — | — | EP | disclosed |
| US-6921756-B2 | Inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2005-07-26 | — | — | US | disclosed |
| US-6884791-B2 | Inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2005-04-26 | — | — | US | disclosed |
| US-20050043276-A1 | Novel inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2005-02-24 | — | — | US | disclosed |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | METHYLGENE, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040059115-A1 | Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-03-25 | — | — | US | disclosed |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| US-6472406-B1 | Sulfonamidomethyl phosphonate inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043276-A1 | Novel inhibitors of beta-lactamase | MGAM, LSS, CYP51A1 | CA2 2716/4885CA1 4384/4885CES2 174/4885 |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, COASY | CA2 2629/4885CA1 4178/4885CES2 176/4885 |
| US-20060105999-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, LCT | CA2 2457/4885CA1 4321/4885CES2 178/4885 |
| US-20040059115-A1 | Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase | PGLS, MGAM, STS | CA2 2859/4885CA1 4176/4885CES2 324/4885 |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | MGAM, LSS, CYP51A1 | CA2 2716/4885CA1 4384/4885CES2 174/4885 |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | LSS, MGAM, COASY | CA2 2498/4885CA1 4194/4885CES2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.